{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:52:52Z","timestamp":1789440772938,"version":"build-2803163510"},"reference-count":28,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"Adaptimmune"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,6,3]]},"DOI":"10.1080\/14737140.2025.2612043","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T08:08:52Z","timestamp":1767168532000},"page":"661-670","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["An evaluation of afamitresgene autoleucel for the treatment of advanced synovial sarcoma and myxoid round cell liposarcoma"],"prefix":"10.1080","volume":"26","author":[{"given":"Margaux","family":"Dupont","sequence":"first","affiliation":[{"name":"Centre Leon Berard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[{"name":"Centre Leon Berard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Brahmi","sequence":"additional","affiliation":[{"name":"Centre Leon Berard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Romeo","sequence":"additional","affiliation":[{"name":"Centre Leon Berard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"Centre Leon Berard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246958"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101403"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100402"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0831-7"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10556-4"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.014"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001152"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30624-1"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-024-00749-3"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102891"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000541"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.006"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101265"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02128-z"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00753"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.58347\/tml.2024.1713i"},{"key":"e_1_3_4_19_1","volume-title":"50th Annual ONS Congress","author":"Downey-Freiman T","year":"2025","unstructured":"Downey-Freiman T, McLaughlin P, Pudel M, et al. Nursing considerations for cell therapy with Afamitresgene autoleucel (afami-cel) in patients with solid tumors. 50th Annual ONS Congress; Colorado Conference Center. 2025. https:\/\/ons.confex.com\/ons\/2025\/meetingapp.cgi\/Paper\/15917"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0762-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00411-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17071054"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0595"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e23560"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103645"},{"key":"e_1_3_4_26_1","unstructured":"Adaptimmune. A phase 1 dose escalation study to assess safety and efficacy of ADP-A2M4CD8 as monotherapy or in combination with either nivolumab or pembrolizumab in HLA-A2+ subjects with MAGE-A4 positive tumors (SURPASS). Report No.: nCT04044859. clinicaltrials.gov; 2025 mar [cited 2025 oct 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04044859"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS708"},{"key":"e_1_3_4_28_1","unstructured":"Adaptimmune. A phase 2 open-label randomized non-comparative clinical trial of ADP-A2M4CD8 Monotherapy and in combination with nivolumab in subjects with recurrent ovarian cancers. Report No.: nCT05601752. clinicaltrials.gov; 2024 d\u00e9c [cited 2025 oct 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05601752"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.01.380"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2612043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:18:19Z","timestamp":1780305499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2612043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,3]]}},"alternative-id":["10.1080\/14737140.2025.2612043"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2612043","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}